Heterogeneous assay for pyrophosphate detection
AssigneeLI-COR, Inc.
InventorJohn G. K. Williams
Life of this patent
Estimating the term…
Loading patent…
AssigneeLI-COR, Inc.
InventorJohn G. K. Williams
Estimating the term…
Nucleotide triphosphate probes containing a fluorophore attached to the β-phosphate and a quencher moiety sufficiently proximal to the fluorophore moiety for use in pyrophosphate detection assays are disclosed. These probes exhibit distinguishable fluorescence characteristics when the fluorophore is attached to the nucleotide through the γ-phosphate and when it is unattached to the nucleotide. The present invention also provides kits and integrated systems for practicing the assays described herein.
A heterogeneous assay method for detecting pyrophosphate cleavage, the components of the assay comprising a labeled NTP, a target nucleic acid, a primer nucleic acid and a polymerase, said method comprising:
A nucleotide triphosphate (NTP) probe, said NTP probe consisting of:
A kit for assaying pyrophosphate cleavage, said kit comprising:
Dependencies are inferred from the claim text.
From the US filing history. Foreign family members aren’t listed.
Methods for sequencing: involving nucleic acid arrays, e.g. sequencing by hybridisation
With substituted hydrocarbon radicals attached to carbon atoms of the hetero ring: radicals substituted by oxygen atoms
Pyrimidine radicals: with the saccharide radical esterified by phosphoric or polyphosphoric acids
Purine radicals: with the saccharide radical esterified by phosphoric or polyphosphoric acids
Term ended 13 Dec 2019 (estimated)
USPTO file history isn’t available for this patent, so only indexed dates are shown.
This invention relates generally to a heterogeneous assay, and in particular, to assay methods using fluorescent nucleotide triphosphates having a fluorophore moiety attached to the γ-phosphate that are especially useful for pyrophosphate detection.
The primary sequences of nucleic acids are crucial for understanding the function and control of genes and for applying many of the basic techniques of molecular biology. The ability to do rapid and reliable DNA sequencing is therefore a very important technology. The DNA sequence is an important tool in genomic analysis as well as other applications, such as genetic identification, forensic analysis, genetic counseling, medical diagnostics, etc. With respect to the area of medical diagnostic sequencing, disorders, susceptibilities to disorders, and prognoses of disease conditions, can be correlated with the presence of particular DNA sequences, or the degree of variation (or mutation) in DNA sequences, at one or more genetic loci. Examples of such phenomena include human leukocyte antigen (HLA) typing, cystic fibrosis, tumor progression and heterogeneity, p53 proto-oncogene mutations and ras proto-oncogene mutations (see, Gyllensten et al., PCR Methods and Applications, 1: 91-98 (1991); U.S. Pat. No. 5,578,443, issued to Santamaria et al.; and U.S. Pat. No. 5,776,677, issued to Tsui et al.).
Various approaches to DNA sequencing exist. The dideoxy chain termination method serves as the basis for all currently available automated DNA sequencing machines. (see, Sanger et al., Proc. Natl. Acad. Sci., 74: 5463-5467 (1977); Church et al., Science, 240: 185-188 (1988); and Hunkapiller et al., Science, 254: 59-67 (1991)). Other methods include the chemical degradation method, (see, Maxam et al., Proc. Natl. Acad. Sci., 74: 560-564 (1977), whole-genome approaches (see, Fleischmann et al., Science, 269, 496 (1995)), expressed sequence tag sequencing (see, Velculescu et al, Science, 270, (1995)), array methods based on sequencing by hybridization (see, Koster et al., Nature Biotechnology, 14, 1123 (1996)), and single molecule sequencing (SMS) (see, Jett et al., J. Biomol. Struct. Dyn. 7, 301 (1989) and Schecker et al., Proc. SPIE-Int. Soc. Opt. Eng. 2386, 4 (1995)).
FIG. 1 Panel A illustrates pyrophosphate cleavage with a polymerase; Panel B illustrates an embodiment of the present invention.
FIG. 2 Panel A illustrates an optical set of the present invention; Panel B illustrates a single molecule sequencing embodiment of the present invention; Panel C illustrates an embodiment of the present invention.
FIG. 3 illustrates DABCYL and dinitrophenyl derivatives of the present invention.
The term “heterogeneous” assay as used herein refers to an assay method wherein at least one of the reactants in the assay mixture is attached to a solid phase, such as a solid support.
The term “oligonucleotide” as used herein includes linear oligomers of nucleotides or analogs thereof, including deoxyribonucleosides, ribonucleosides, and the like. Usually, oligonucleotides range in size from a few monomeric units, e.g. 3-4, to several hundreds of monomeric units. Whenever an oligonucleotide is represented by a sequence of letters, such as “ATGCCTG,” it will be understood that the nucleotides are in 5′-3′ order from left to right and that “A” denotes deoxyadenosine, “C” denotes deoxycytidine, “G” denotes deoxyguanosine, and “T” denotes thymidine, unless otherwise noted.
The term “nucleoside” as used herein refers to a compound consisting of a purine, deazapurine, or pyrimidine nucleoside base, e.g., adenine, guanine, cytosine, uracil, thymine, deazaadenine, deazaguanosine, and the like, linked to a pentose at the 1′ position, including 2′-deoxy and 2′-hydroxyl forms, e.g., as described in Kornberg and Baker, DNA Replication, 2nd Ed. (Freeman, San Francisco, 1992).